Clay Siegall is currently the Chief Executive Officer and President of Seattle Genetics. Clay co-founded Seattle Genetics in the year 1998, and since then, he has also served as the Chairman of the board of directors. The company has worked under the leadership of Dr. Siegall to develop a diverse portfolio of preclinical and clinical products that target several cancers and other autoimmune indications.
Seattle Genetics is now leading in the antibody technologies. The first drug from the firm is known as Adcetris. The antibody conjugate from the institution is doing quite well in the market, and it is also helping many people in more than sixty countries in dealing with cancer.
Clay Siegall is also responsible for raising capital for Seattle Genetics. He has led several capital raising operations for the institutions, managing to secure over three hundred and thirty million dollars in both private and public financing.
Apart from raising capital for the company, Clay Siegall has led the company to enter into several strategic collaborations such as the exclusive international partnerships agreement with the Genentech got SGN-40 that was valued at over eight hundred and sixty million dollars and the progenies that have brought over sixty million dollars.
Joe Biden, the Vice President of the United States visited the Seattle Genetics region to recognize the efforts of the company. The visit brought the company into the limelight, and several projects of the company came up. The institution issued a statement concerning its future plans.
The CEO of the biotechnology company announced that Seattle Genetics was going to develop twelve therapies that would be used to treat different types of cancers affecting consumers in the modern times. Clay Siegall revealed that his company was testing its first drug first, and it the tests is positive, and the rest will be introduced soon.
Seattle Genetics will also be increasing its employees in the recent future to ensure that the production of the new drugs is successful.